Eltrekibart is a novel monoclonal antibody that binds to the ligands that signal CXCR1 and CXCR2. 65.6% of patients taking eltrekibart achieved a Hidradenitis Suppurativa Clinical Response score ...

The company’s lead asset, a CXCR2 antagonist dubbed RIST4721, was undergoing phase 2 trials for four neutrophil-mediated diseases: a rare inflammatory disorder called palmoplantar pustulosis ...

These cells harbor a different receptor called CXCR2 that contributes to their survival and progression, the researchers described in a study published in the journal Science Translational Medicine.

Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy. This is an ASCO Meeting Abstract from the 2023 ...

Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab (Pembro) in patients with advanced melanoma. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This ...

G protein-coupled receptors (GPCRs) are involved in many diseases, yet raising therapeutic antibodies against them is notoriously difficult because the transmembrane receptors contain only short ...

Leucid Bio has dosed the first patient in its Phase 1 AERIAL trial of LEU011, an NKG2D-targeting CAR-T therapy for solid ...